tocilizumab · TOCILIZUMAB 400 mg/20mL · Injection, Solution · Intravenous · CELLTRION USA, Inc.
NDC 72606-0044-01 · 1 VIAL, SINGLE-DOSE in 1 CARTON / 20 mL in 1 VIAL, SINGLE-DOSE · BLA · View full market →
Just 3 companies supply this market — thin enough that a single exit would be felt immediately. Historically, drugs in this position went on to a new shortage within 90 days about 0.4% of the time — roughly 3× the typical drug (0.1%).
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Not scored — fragility is computed for NADAC-priced NDCs.
sterile injectable · sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is 3× that.
Backtested statistical model over the whole market, not this package alone. Model details →
There's no legal definition — it meets 3 of 6 public criteria. Why that matters →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Genentech, Inc. | TOCILIZUMAB 162 mg/.9mL | Jul 15, 2026 | Sep 3, 2026 |
| CELLTRION USA, Inc. | TOCILIZUMAB 162 mg/.9mL | Jul 15, 2026 | Sep 2, 2026 |
| CELLTRION USA, Inc. | TOCILIZUMAB 200 mg/10mL | Jul 15, 2026 | Sep 2, 2026 |
| CELLTRION USA, Inc. | TOCILIZUMAB 400 mg/20mL | Jul 15, 2026 | Sep 2, 2026 |
| CELLTRION USA, Inc. | TOCILIZUMAB 80 mg/4mL | Jul 15, 2026 | Sep 2, 2026 |
| Chugai Pharmaceutical Co., Ltd. | TOCILIZUMAB 162 mg/.9mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Avtozma — NDC 72606-0044-01," retrieved September 3, 2026, https://drugdashboards.com/drug/72606004401.
Free to cite with attribution — see how the data is put together.